The Food and Drug Administration (FDA) recently approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the association of the HLA-B*5701 allele and hypersensitivity reactions caused by abacavir-containing therapy. 

For urgent clinical updates from the Centers for Disease Control and Prevention (CDC) and FDA, IDSA offers two e-mail services to help members stay informed.  IDSA members can sign up for this service online. (You must be logged in to have access to this link.)

< Previous Article | Next Article >